Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

Amarin (NASDAQ:AMRN) reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market...

What Amarin (AMRN) Said on Its Q3 Earnings Call ↗

October 28, 2026

Via MarketBeat

Performance

52-Week Range 28.6% below 52-week high

12.37

11.2552W Low 17.3152W High

1 Week 6.2% below 1-week high

11.851W Low 13.181W High

Amarin Corporation plc - American Depositary Shares (AMRN) traded between $11.25 and $17.31 over the past 52 weeks and last traded at $12.37, 28.6% below its 52-week high. Over the past week it ranged between $11.85 and $13.18.

Past 12 Months

-3.0%

+2.3%

-14.1%

-14.7%

-9.9%

-21.0%

1W -$0.38

1M +$0.28

3M -$2.03

6M -$2.13

YTD -$1.35

1Y -$3.29

AMRN was -21.0% over the past year, -14.7% over six months, -9.9% year to date, -3.0% in the last week.

12 Months vs Market

AMRN

-21.0%

DIA

+12.4%

SPY

+12.5%

QQQ

+9.6%

IWM

+15.9%

Over the past 12 months AMRN returned -21.0% versus DIA (Dow) +12.4%, SPY (S&P 500) +12.5%, QQQ (Nasdaq 100) +9.6% and IWM (Russell 2000) +15.9%.

Volume & Liquidity 0.51× 3-mo avg

Today 35,120 3-mo avg 69.3K

98.9K

73.6K

69.3K

71.3K

YTD

75.6K

78.3K

AMRN most recently traded 35,120 shares against a 3-month average daily volume of 69.3K.

More News

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income

October 28, 2026

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer

October 25, 2026

Amarin Posts Surprise Q2 Profit on Cost Discipline, Shares Rise Pre-Market (NASDAQ:AMRN) ↗

July 29, 2026

Via Chartmill

Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs ↗

April 29, 2026

Via Chartmill

Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026

October 21, 2026

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

August 31, 2026

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

August 28, 2026

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

August 24, 2026

Amarin (AMRN) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

July 29, 2026

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

July 15, 2026

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

June 30, 2026

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

May 27, 2026

Amarin (AMRN) Q1 2026 Earnings Transcript ↗

April 30, 2026

Amarin Reports 2026 First Quarter Financial Results

April 29, 2026

Amarin (AMRN) Q2 2025 Earnings Transcript ↗

April 21, 2026

Amarin (AMRN) Q3 2025 Earnings Transcript ↗

April 21, 2026

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

April 15, 2026

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

March 18, 2026

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual

March 16, 2026

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks ↗

March 07, 2026